Diabetes, Cardiovascular Risks, and Lipoproteins
Diabetes, Cardiovascular Risks, and Lipoproteins is a research topic within Endocrinology, Diabetes and Metabolism. Science Explorer counts 60k research works in it since 1950. 24.2% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the metabolic syndrome, its association with cardiovascular disease, diabetes, insulin resistance, obesity, and atherosclerosis. It includes studies on glucose metabolism, lifestyle interventions, and global prevalence of related conditions.
- Metabolic Syndrome
- Cardiovascular Disease
- Diabetes
- Insulin Resistance
- Obesity
- Glucose Metabolism
- Atherosclerosis
- Lifestyle Intervention
- Cholesterol
- Global Prevalence
- Research works
- 60k fractional, since 1950
- In the world top 10%
- 15k per year above
- Top-10% rate
- 24.2% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +11% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Diabetes, Cardiovascular Risks, and Lipoproteins research?
By volume, China and the United States publish the most (2.2k and 1.5k works in 2022–2025).
By volume, 2022–2025
- 1 China 2.2k works
- 2 United States 1.5k works
- 3 India 832 works
- 4 Indonesia 514 works
- 5 United Kingdom 372 works
- 6 South Korea 325 works
- 7 Japan 317 works
- 8 Iran 294 works
- 9 Spain 257 works
- 10 Italy 229 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Diabetes, Cardiovascular Risks, and Lipoproteins research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Diabetes, Cardiovascular Risks, and Lipoproteins research, followed by Capital Medical University and Peking University.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 58 works
- 2 Capital Medical UniversityChina 42 works
- 3 Peking UniversityChina 37 works
- 4 Tehran University of Medical SciencesIran 37 works
- 5 Nanjing Medical UniversityChina 33 works
- 6 Harvard UniversityUnited States 30 works
- 7 Shahid Beheshti University of Medical SciencesIran 29 works
- 8 University of North Carolina at Chapel HillUnited States 29 works
- 9 Sun Yat-sen UniversityChina 28 works
- 10 Central South UniversityChina 28 works
Who are the leading researchers in Diabetes, Cardiovascular Risks, and Lipoproteins?
The most-cited researchers publishing on Diabetes, Cardiovascular Risks, and Lipoproteins include Sadaf G Sepanlou, Erkin М Мirrakhimov and Isabela M. Benseñor.
- 1 Sadaf G Sepanlou Iran 8k citations
- 2 Erkin М Мirrakhimov Kyrgyzstan 7.8k citations
- 3 Isabela M. Benseñor Brazil 7.7k citations
- 4 Yousef Khader Jordan 7.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Diabetes, Cardiovascular Risks, and Lipoproteins research done?
The largest centres of Diabetes, Cardiovascular Risks, and Lipoproteins research in 2022–2025 are Beijing (China), Seoul (South Korea), Shanghai (China) and Guangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Tangshan.
Largest cities, 2022–2025
Where it is the local speciality
- TangshanCN · 26.9 works10×
Location quotient: how much more of its research is in Diabetes, Cardiovascular Risks, and Lipoproteins than the world average.
Where is the best place to study Diabetes, Cardiovascular Risks, and Lipoproteins?
Among universities, judged by research, Chinese Academy of Medical Sciences & Peking Union Medical College, Capital Medical University and University of Gondar score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 61.9 | 38.2% | 5.7× | 58 | +72.5% |
| 2 | Capital Medical UniversityChina | 58.4 | 35.4% | 6.9× | 42 | +40.0% |
| 3 | University of GondarEthiopia | 58.1 | 21.4% | 9.7× | 15 | +340.5% |
| 4 | Nanjing Medical UniversityChina | 56.3 | 31.7% | 6.2× | 33 | +112.5% |
| 5 | Shahid Sadoughi University of Medical Sciences and Health ServicesIran | 54.6 | 27.4% | 9.6× | 9 | +205.9% |
| 6 | Tehran University of Medical SciencesIran | 54.0 | 25.0% | 7.5× | 37 | +34.4% |
| 7 | Soongsil UniversitySouth Korea | 53.1 | 33.9% | 10.4× | 12 | — |
| 8 | Beijing University of Chinese MedicineChina | 53.1 | 60.3% | 5.7× | 10 | — |
| 9 | Aga Khan UniversityPakistan | 51.9 | 36.9% | 10.0× | 9 | -9.3% |
| 10 | Shahid Beheshti University of Medical SciencesIran | 51.5 | 21.8% | 7.9× | 29 | +47.0% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Diabetes, Cardiovascular Risks, and Lipoproteins research growing?
Output in 2018–2022 was 11% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Diabetes, Cardiovascular Risks, and Lipoproteins.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.